| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.EJHEART.2005.04.008 |
| P698 | PubMed publication ID | 16087142 |
| P50 | author | Aldo P. Maggioni | Q40310748 |
| Luigi Tavazzi | Q64496908 | ||
| P2093 | author name string | Maria Grazia Franzosi | |
| Gianni Tognoni | |||
| Roberto Marchioli | |||
| Carlo Schweiger | |||
| Alejandro Macchia | |||
| Giacomo Levantesi | |||
| Gian Luigi Nicolosi | |||
| Franco Valagussa | |||
| RosaMaria Marfisi | |||
| Enrico Geraci | |||
| P2860 | cites work | Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico | Q28143207 |
| Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction | Q28208692 | ||
| Atherosclerotic plaque rupture: emerging insights and opportunities | Q33694775 | ||
| Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. | Q33958979 | ||
| Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction | Q33970406 | ||
| Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction | Q34187441 | ||
| Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction | Q34415281 | ||
| Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators | Q34420012 | ||
| Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure | Q34620874 | ||
| A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group | Q34718800 | ||
| Dietary modification of inflammation with lipids. | Q34892966 | ||
| Antiarrhythmic effects of omega-3 fatty acids: from epidemiology to bedside | Q35208804 | ||
| Effect of antiarrhythmic drugs on mortality after myocardial infarction | Q40159319 | ||
| Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials | Q40845893 | ||
| Prevention of cardiac sudden death by N-3 fatty acids: a review of the evidence | Q41033962 | ||
| Antiarrhythmic effects of polyunsaturated fatty acids. Recent studies | Q41139277 | ||
| Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators | Q42550740 | ||
| The Protective Effect of a Small Amount of Fish on Coronary Heart Disease Mortality in an Elderly Population | Q43640567 | ||
| Blood levels of long-chain n-3 fatty acids and the risk of sudden death | Q43955896 | ||
| Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators | Q44086151 | ||
| Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure | Q45011976 | ||
| Fish and omega-3 fatty acid intake and risk of coronary heart disease in women | Q45305759 | ||
| P433 | issue | 5 | |
| P921 | main subject | myocardial infarction | Q12152 |
| systole | Q496359 | ||
| P304 | page(s) | 904-909 | |
| P577 | publication date | 2005-08-01 | |
| P1433 | published in | European Journal of Heart Failure | Q5017954 |
| P1476 | title | Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids | |
| P478 | volume | 7 |
| Q22306358 | 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines |
| Q49939182 | A lower eicosapentaenoic acid/arachidonic acid ratio is associated with in-hospital fatal arrhythmic events in patients with acute myocardial infarction: a J-MINUET substudy. |
| Q43142479 | A new systolic parameter defined as the ratio of brachial pre-ejection period to brachial ejection time predicts overall and cardiovascular mortality in hemodialysis patients. |
| Q82461776 | Antiarrhythmic mechanisms of n-3 PUFA and the results of the GISSI-Prevenzione trial |
| Q64075170 | Benefits of Fasting Abbreviation with Carbohydrates and Omega-3 Infusion During CABG: a Double-Blind Controlled Randomized Trial |
| Q36945230 | Beyond lipids: the role of omega-3 fatty acids from fish oil in the prevention of coronary heart disease. |
| Q37773594 | Cardiovascular effects of marine omega-3 fatty acids. |
| Q37257327 | Concordance of randomized and nonrandomized studies was unrelated to translational patterns of two nutrient-disease associations. |
| Q37859752 | Delayed and indirect effects of antiarrhythmic drugs in reducing sudden cardiac death |
| Q34102651 | Do omega-3 polyunsaturated Fatty acids prevent cardiovascular disease? A review of the randomized clinical trials |
| Q43290976 | Effect of fish oil (n-3 polyunsaturated fatty acids) on plasma lipids, lipoproteins and inflammatory markers in HIV-infected patients treated with antiretroviral therapy: a randomized, double-blind, placebo-controlled study |
| Q45934157 | Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial. |
| Q44329632 | Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial |
| Q60402390 | Effects of n-3 PUFA on insulin resistance after an oral fat load |
| Q38086841 | Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy |
| Q34986662 | Fish oil in primary and secondary cardiovascular prevention |
| Q86118649 | Fish oils, coronary heart disease, and the environment |
| Q36327925 | Fish-oil supplementation in patients with implantable cardioverter defibrillators: a meta-analysis |
| Q37288199 | Heterogeneity in randomized controlled trials of long chain (fish) omega-3 fatty acids in restenosis, secondary prevention and ventricular arrhythmias |
| Q37154249 | Impaired Myocardial Bioenergetics in HFpEF and the Role of Antioxidants |
| Q41686228 | Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. |
| Q41102448 | Long-Term Administration of Eicosapentaenoic Acid Improves Post-Myocardial Infarction Cardiac Remodeling in Mice by Regulating Macrophage Polarization |
| Q30251589 | Marine omega-3 highly unsaturated fatty acids: From mechanisms to clinical implications in heart failure and arrhythmias. |
| Q36886923 | N-3 polyunsaturated fatty acids attenuates triglyceride and inflammatory factors level in hfat-1 transgenic pigs |
| Q33664290 | Natural Products in Epilepsy-the Present Situation and Perspectives for the Future |
| Q48749026 | No effect of n-3 fatty acids supplementation on NT-proBNP after myocardial infarction: the Alpha Omega Trial. |
| Q45386825 | Omega 3 : where do we stand? |
| Q38271779 | Omega-3 Fatty Acids and Primary and Secondary Prevention of Cardiovascular Disease |
| Q37507934 | Omega-3 ethylester concentrate: a review of its use in secondary prevention post-myocardial infarction and the treatment of hypertriglyceridaemia |
| Q82057887 | Omega-3 fatty acid supplementation for the prevention of arrhythmias |
| Q37620445 | Omega-3 fatty acids and heart failure |
| Q37367669 | Omega-3 polyunsaturated fatty acids: a necessity for a comprehensive secondary prevention strategy |
| Q38859866 | Phase 4 Studies in Heart Failure - What is Done and What is Needed? |
| Q42709048 | Polyunsaturated fatty acids in heart failure: should we give more and give earlier? |
| Q33582418 | Preoperative carbohydrate load and intraoperatively infused omega-3 polyunsaturated fatty acids positively impact nosocomial morbidity after coronary artery bypass grafting: a double-blind controlled randomized trial |
| Q36237366 | The Role of Omega-3 Polyunsaturated Fatty Acids in Heart Failure: A Meta-Analysis of Randomised Controlled Trials |
| Q49141144 | The role of iron, omega-3 Fatty acids, and vitamins in heart failure. |
| Q34418028 | Uses and benefits of omega-3 ethyl esters in patients with cardiovascular disease. |
| Q36064570 | Why Do We Still Need Large Scale Clinical Trial: The Case of n-3 PUFA. |
| Q36661439 | n-3 Fatty acids and cardiovascular disease: actions and molecular mechanisms |
| Q39041784 | ω3-Polyunsaturated fatty acids for heart failure: Effects of dose on efficacy and novel signaling through free fatty acid receptor 4. |
Search more.